Alpha Biopharma is focused on developing innovative therapies, particularly in the field of oncology. Their lead candidate, Zorifertinib, is a next-generation EGFR tyrosine kinase inhibitor (TKI) specifically designed for treating advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. This drug boasts a remarkable 100% blood-brain barrier penetration rate, making it a significant advancement in the treatment of lung cancer that has spread to the brain. Zorifertinib has received support from national funding initiatives aimed at fostering the development of major new drugs, highlighting its potential impact in addressing critical medical needs.

In addition to Zorifertinib, Alpha Biopharma is also engaged in the development of cell therapies, particularly focusing on natural killer (NK) cell-based treatments. Their research includes the use of memory-like NK cells, which have shown promise in inducing remissions in patients with leukemia. The company is exploring various strategies to enhance the efficacy of these immune cells, including the combination of cytokines to improve their responses against cancer. This dual focus on both targeted therapies and immunotherapy positions Alpha Biopharma as a key player in the advancement of cancer treatment options.

China

Alpha Biopharma – Specialized in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha Biopharma establishes strategic partnership with leading international pharmaceutical company/R&D institute.

Alpha Biopharma

Company Details